Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has entered into a private placement pursuant to a securities purchase
Ocean Biomedical announces private placement of $25 mln convertible notes
Categories
Biotechnology
Earnings: Regeneron Pharmaceuticals (REGN) Q1 profit falls; revenue up 7%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported a decline in adjusted earnings for the first quarter of 2023, despite an increase
Corcept Therapeutics Incorporated (CORT) Q1 2023 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ: CORT) Q1 2023 Earnings Call dated May. 03, 2023 Corporate participants: Atabak Mokari -- Chief Financial Officer Charlie
A snapshot of AmerisourceBergen’s Q2 2023 earnings results
Pharmaceutical solutions provider AmerisourceBergen Corporation (NYSE: ABC) reported higher revenues and adjusted earnings for the second quarter of 2023. Second-quarter revenue increased
VRTX Earnings: A snapshot of Vertex Pharmaceuticals’ Q1 2023 results
Healthcare firm Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on Monday reported a decline in adjusted earnings for the first quarter, despite an increase in
Trxade Health Inc. (NASDAQ: MEDS) Q1 2023 Research Summary
Trxade Health Inc. (NASDAQ: MEDS) is a healthcare IT company that operates as an integrated drug procurement and delivery platform. It is
AMGN Earnings: Everything you need to know about Amgen’s Q1 results
Amgen Inc. (NASDAQ: AMGN) has reported lower revenues and adjusted earnings for the first quarter of 2023. The biotechnology firm also provided
Bristol-Myers Squibb (BMY) reports higher Q1 profit; revenue down 3%
Biotechnology company Bristol Myers Squibb (NYSE: BMY) said its first-quarter adjusted earnings increased modestly, despite a decline in revenues. Net income attributable
MRK Earnings: Highlights of Merck’s Q1 2023 financial results
Pharma firm Merck & Co., Inc. (NYSE: MRK) on Thursday reported lower earnings for the first quarter of 2023, due to a sharp
Earnings: Highlights of Eli Lilly & Company’s (LLY) Q1 2023 results
Eli Lilly and Company (NYSE: LLY) on Thursday reported lower earnings and revenues for the first quarter of 2023. The company also
Ocean Biomedical reports new results validating tumor suppression with anti-Chi3L1 antibody: EF Hutton raises OCEA price target to $17
Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said its scientific co-founder Jack Elias published new findings in Cancer Research, a peer-reviewed
ABBV Infographic: AbbVie’s Q1 2023 earnings and revenue decline
Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a decrease in first-quarter 2023 adjusted earnings and revenues. The company also provided guidance for
Eli Lilly and Company (LLY) Q1 2023 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q1 2023 Earnings Call dated Apr. 27, 2023 Corporate Participants: Joe Fletcher -- Senior Vice President
BSX Earnings: Highlights of Boston Scientific’s Q1 2023 results
Medical device maker Boston Scientific Corporation (NYSE: BSX) reported financial results for the first quarter of 2023. The company also provided guidance for
Illumina Inc (ILMN) Q1 2023 Earnings Call Transcript
Illumina Inc (NASDAQ: ILMN) Q1 2023 earnings call dated Apr. 25, 2023 Corporate Participants: Salli Schwartz -- Vice President of Investor Relations Francis deSouza -- Chief
Ocean Biomedical co-founder Jonathan Kurtis presents detailed data on malaria vaccine at conference
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Ocean Biomedical co-founder Jack Elias to receive US patent for pulmonary fibrosis treatments
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Ocean Biomedical (OCEA) announces $134 million financial backing for innovative research and IND filings
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers for developing and commercializing their discoveries,
Ocean Biomedical gets Notice of Allowance for US patent application for developing new malaria therapeutics
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers for developing and commercializing their discoveries,
Bio Path Holdings Inc (BPTH) Q4 2022 Earnings Call Transcript
Bio Path Holdings Inc (NASDAQ: BPTH) Q4 2022 earnings call dated Mar. 31, 2023 Corporate Participants: Will O'Connor -- Investor Relations Peter Nielsen -- Chief Executive
TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel
TC BioPharm (NASDAQ: TCBP) is a clinical-stage cell therapy company focused on the development of treatments for infectious diseases, including advanced allogeneic